Michael Ong Andrea Marie Ibrahim Samuel Bourassa-Blanchette Christina Canil Todd Fairhead Greg Knoll
10.1186/s40425-016-0171-8
J Immunother Cancer
2016 Oct 18;4:64.
acute allograft rejection anti-pd-1 therapy hemodialysis melanoma nivolumab organ transplant
CC BY
https://pubmed.ncbi.nlm.nih.gov/27777773/
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Graft Rejection / drug therapy Graft Rejection / immunology Kidney Transplantation / adverse effects Renal Dialysis
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Graft Rejection / drug therapy Graft Rejection / immunology Kidney Transplantation / adverse effects Renal Dialysis Case Reports Antibodies, Monoclonal / pharmacology Antineoplastic Agents, Immunological / pharmacology Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 1 / therapy Female Humans Immunosuppressive Agents / adverse effects Immunosuppressive Agents / therapeutic use Lung Neoplasms / diagnosis Lung Neoplasms / drug therapy Lung Neoplasms / secondary Melanoma / drug therapy Melanoma / etiology Melanoma / pathology Middle Aged Molecular Targeted Therapy Neoplasm Staging Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy Skin Neoplasms / etiology Skin Neoplasms / pathology Tomography, X-Ray Computed Antibodies, Monoclonal Antineoplastic Agents, Immunological Immunosuppressive Agents Programmed Cell Death 1 Receptor Nivolumab Melanoma, Cutaneous Malignant
PMC5067882
27777773
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
2016